Literature DB >> 22269403

Pro-apoptotic effects of Paecilomyces hepiali, a Cordyceps sinensis extract on human lung adenocarcinoma A549 cells in vitro.

Asmitananda Thakur1, Ren Hui, Zhang Hongyan, Yang Tian, Chen Tianjun, Chen Mingwei.   

Abstract

BACKGROUND: Paecilomyces hepiali (PH) is a derivative of Cordyceps sinensis (CS), a fungus that has been shown to have anti-cancer and pro-apoptotic effects. Here, we aimed to investigate the effect of in vitro PH treatment on cell proliferation, cell cycling, apoptosis, and tumor necrosis factor-alfa (TNF-α) mRNA expression in human lung adenocarcinoma A549 cells (A549).
MATERIALS AND METHODS: A549 cells were treated with an aqueous extract of PH at concentrations of 0.25, 0.5, 1, 2, and 4 mg/ml. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to evaluate cellular viability and proliferation, while flow cytometry (FCM) was used to examine cell cycling. Apoptosis was assayed using Annexin V Fluorescein Isothiocyanate / Propidium Iodide (V-FITC/PI) and FCM. TNF-α mRNA expression was measured with reverse transcriptase-polymerase chain reaction (RT-PCR).
RESULTS: Cell proliferation was significantly suppressed by treatment with 1, 2, and 4 mg/ml of PH extract. Furthermore, the MTT assay showed that cell proliferation was inhibited in a concentration-time-dependent manner. As the concentration of the PH treatment increased, there were fewer cells in the S phase, and more cells in the G0/G1 and G2 phases. After 24 h of treatment, apoptosis was induced by a dose of 2 mg/ml of PH. TNF-α mRNA expression was significantly higher in the intervention groups and was positively associated with treatment concentration.
CONCLUSIONS: These results indicate that in vitro treatment with an aqueous extract from PH limits cell proliferation, induces apoptosis, and causes cell cycle arrest of A549 cells; this suggests that it may have potential as a therapy for lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22269403     DOI: 10.4103/0973-1482.92007

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  7 in total

1.  Pharmacological and therapeutic potential of Cordyceps with special reference to Cordycepin.

Authors:  Hardeep S Tuli; Sardul S Sandhu; A K Sharma
Journal:  3 Biotech       Date:  2013-02-19       Impact factor: 2.406

2.  Anti-inflammatory effects of Cordyceps mycelium (Paecilomyces hepiali, CBG-CS-2) in Raw264.7 murine macrophages.

Authors:  Seong-Yeol Park; Su-Jin Jung; Ki-Chan Ha; Hong-Sig Sin; Seung-Hwan Jang; Han-Jung Chae; Soo-Wan Chae
Journal:  Orient Pharm Exp Med       Date:  2014-12-05

Review 3.  Cordyceps industry in China.

Authors:  Caihong Dong; Suping Guo; Wenfeng Wang; Xingzhong Liu
Journal:  Mycology       Date:  2015-05-21

4.  Discriminatory Power Evaluation of Nuclear Ribosomal RNA Barcoding Sequences Through Ophiocordyceps sinensis Related Samples.

Authors:  Ping Zhang; Shenghui Cui; Xiu Ren; Shuai Kang; Feng Wei; Shuangcheng Ma; Bin Liu
Journal:  Front Microbiol       Date:  2018-10-23       Impact factor: 5.640

5.  A Case of Stage IV Non-Small Cell Lung Cancer Treated with Korean Medicine Therapy Alone.

Authors:  Dong-Hyun Lee; Shin Seong; Sung-Su Kim; Jae-Bok Han
Journal:  Case Rep Oncol       Date:  2013-11-15

6.  Studies on the Antidiabetic and Antinephritic Activities of Paecilomyces hepiali Water Extract in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats.

Authors:  Juan Wang; Lirong Teng; Yange Liu; Wenji Hu; Wenqi Chen; Xi Hu; Yingwu Wang; Di Wang
Journal:  J Diabetes Res       Date:  2016-02-29       Impact factor: 4.011

7.  Anticancer Efficacy of Cordyceps militaris Ethanol Extract in a Xenografted Leukemia Model.

Authors:  Jae Gwang Park; Young-Jin Son; Tae Ho Lee; Nam Joon Baek; Deok Hyo Yoon; Tae Woong Kim; Adithan Aravinthan; Sungyoul Hong; Jong-Hoon Kim; Gi-Ho Sung; Jae Youl Cho
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-06       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.